141 related articles for article (PubMed ID: 26671852)
1. Prediction of iodine-131 biokinetics and radiation doses from therapy on the basis of tracer studies: an important question for therapy planning in nuclear medicine.
Willegaignon J; Pelissoni RA; Lima BC; Sapienza MT; Coura-Filho GB; Buchpiguel CA
Nucl Med Commun; 2016 May; 37(5):473-9. PubMed ID: 26671852
[TBL] [Abstract][Full Text] [Related]
2. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
3. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
5. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Eschner W; Kobe C; Schicha H
Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
[TBL] [Abstract][Full Text] [Related]
6. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies.
DeNardo DA; DeNardo GL; Yuan A; Shen S; DeNardo SJ; Macey DJ; Lamborn KR; Mahe M; Groch MW; Erwin WD
J Nucl Med; 1996 Dec; 37(12):1970-5. PubMed ID: 8970516
[TBL] [Abstract][Full Text] [Related]
7. Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning.
Willegaignon J; Sapienza MT; Coura-Filho GB; Watanabe T; Traino AC; Buchpiguel CA
Med Phys; 2014 Jan; 41(1):012503. PubMed ID: 24387527
[TBL] [Abstract][Full Text] [Related]
8. PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab.
Makris NE; Boellaard R; van Lingen A; Lammertsma AA; van Dongen GA; Verheul HM; Menke CW; Huisman MC
J Nucl Med; 2015 Feb; 56(2):249-54. PubMed ID: 25613538
[TBL] [Abstract][Full Text] [Related]
9. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants.
Lassmann M; Luster M; Hänscheid H; Reiners C
J Nucl Med; 2004 Apr; 45(4):619-25. PubMed ID: 15073258
[TBL] [Abstract][Full Text] [Related]
10. Is it necessary to reduce the radioiodine dose in patients with thyroid cancer and renal failure?
Willegaignon J; Ribeiro VP; Sapienza M; Ono C; Watanabe T; Buchpiguel C
Arq Bras Endocrinol Metabol; 2010 Jun; 54(4):413-8. PubMed ID: 20625654
[TBL] [Abstract][Full Text] [Related]
11. Red marrow and blood dosimetry in (131)I treatment of metastatic thyroid carcinoma: pre-treatment versus in-therapy results.
Giostra A; Richetta E; Pasquino M; Miranti A; Cutaia C; Brusasco G; Pellerito RE; Stasi M
Phys Med Biol; 2016 Jun; 61(11):4316-26. PubMed ID: 27200493
[TBL] [Abstract][Full Text] [Related]
12. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
[TBL] [Abstract][Full Text] [Related]
13. Optimized radioiodine therapy for Graves' disease: two MIRD-based models for the computation of patient-specific therapeutic 131I activity.
Carlier T; Salaun PY; Cavarec MB; Valette F; Turzo A; Bardiès M; Bizais Y; Couturier O
Nucl Med Commun; 2006 Jul; 27(7):559-66. PubMed ID: 16794516
[TBL] [Abstract][Full Text] [Related]
14. Estimating (131)I biokinetics and radiation doses to the red marrow and whole body in thyroid cancer patients: probe detection versus image quantification.
Willegaignon J; Pelissoni RA; Lima BC; Sapienza MT; Coura-Filho GB; Queiroz MA; Buchpiguel CA
Radiol Bras; 2016; 49(3):150-7. PubMed ID: 27403014
[TBL] [Abstract][Full Text] [Related]
15. Management of 131I therapy for thyroid cancer: cumulative dose from in-patients, discharge planning and personnel requirements.
Pacilio M; Bianciardi L; Panichelli V; Argirò G; Cipriani C
Nucl Med Commun; 2005 Jul; 26(7):623-31. PubMed ID: 15942483
[TBL] [Abstract][Full Text] [Related]
16. Para-[(123)I]iodo-L-phenylalanine in patients with pancreatic adenocarcinoma: tumour uptake, whole-body kinetics, dosimetry.
Hellwig D; Gouverneur E; Schaefer A; Raedle J; Menges M; Kirsch CM; Samnick S
Nuklearmedizin; 2008; 47(5):220-4. PubMed ID: 18852930
[TBL] [Abstract][Full Text] [Related]
17. Red bone marrow dose estimation using several internal dosimetry models for prospective dosimetry-oriented radioiodine therapy.
Abuqbeitah M; Demir M; Çavdar İ; Tanyildizi H; Yeyin N; Uslu-Beşli L; Kabasakal L; Işıkcı Nİ; Sönmezoğlu K
Radiat Environ Biophys; 2018 Nov; 57(4):395-404. PubMed ID: 30298289
[TBL] [Abstract][Full Text] [Related]
18. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma.
Hänscheid H; Lassmann M; Luster M; Kloos RT; Reiners C
Endocr Relat Cancer; 2009 Dec; 16(4):1283-9. PubMed ID: 19628649
[TBL] [Abstract][Full Text] [Related]
19. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
20. Comparison of different dosimetric methods for red marrow absorbed dose calculation in thyroid cancer therapy.
Willegaignon J; Sapienza MT; Buchpiguel CA
Radiat Prot Dosimetry; 2012 Apr; 149(2):138-46. PubMed ID: 21586539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
